[Future possibilities of drug therapy of acquired immunodeficiency syndrome].
Human Immunodeficiency Virus replication offers several targets for inhibitory compounds, the foremost presently being the HIV reverse transcriptase. Since the beginning of the epidemic three nucleoside analogue drugs--Zidovudine, Didanosine and Zalcitabine--which act at the reverse transcriptase enzyme are already licensed for use in AIDS-therapy, and others--Stavudine, Alovudine and Lamivudine--are still under clinical evaluation. Although there is a very significant research work for newer drugs for HIV-therapy, it seems that for the next future Zidovudine will remain the most important drug of antiretroviral therapy.
Bálint
G S
GS
Szent-Györgyi Albert Orvostudományi Egyetem, Szeged.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000635:transmission; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D005260:Female; D005544:Forecasting; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000635:transmission; D006801:Humans; D007194:India / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D012106:Research; D014779:Virus Replication / Q000187:drug effects; D014944:World Health Organization
D000998:Antiviral Agents
A szerzett immunhiányos tünetegyüttes gyógyszeres kezelésének jövöbeni lehetöségei.